Elsevier

Fertility and Sterility

Volume 96, Issue 2, August 2011, Pages 498-500.e1
Fertility and Sterility

Original article
Correspondence
Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study

https://doi.org/10.1016/j.fertnstert.2011.05.089Get rights and content
Under an Elsevier user license
open archive

The effect of treatment with percutaneous E2 (100 μg/24 h) during 2 weeks perimenstrually on the number and severity of menstrual migraine attacks was studied in 27 women in a randomized, placebo-controlled, double-blind, crossover trial. We were not able to demonstrate any difference between E2 supplementation and placebo on the number or severity of migraine attacks, but both regimens showed significant effects compared with before treatment.

Clinical Trial Identification Number

NCT00204074.

Key Words

Menstrual migraine
estradiol
RCT

Cited by (0)

A.A-C. has nothing to disclose. M.H. has nothing to disclose. L.L-Å. has nothing to disclose. A-M.L. has nothing to disclose. J.B. has nothing to disclose.

Schering Nordiska, Stockholm, Sweden, kindly supplied patches with E2 or placebo.